NASDAQ · IGMS
Healthcare · Biotechnology
$1.27
Up+$0.00 (+0.00%)
Updated Aug 22, 2026, 8:53 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
IGMS does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning IGMS.
IGMS research
Company profile and research snapshot.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 11, 2025 | Truist Securities | Hold | — |
| Jan 13, 2025 | JP Morgan | Neutral | — |
| Jan 10, 2025 | RBC Capital | Sector Perform | — |
| Jan 10, 2025 | Stifel | Hold | — |
| Jan 10, 2025 | Truist Securities | Hold | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jan 9, 2025
IGM Biosciences is discontinuing the development of its autoimmune disease drug candidates imvotamab and IGM-2644 due to insufficient efficacy. The company is also reducing its workforce by 73% and has $183.8 million in cash and investments as of December 31, 2024.
GlobeNewswire Inc. · Nov 4, 2024
IGM Biosciences, a clinical-stage biotechnology company, announced that it will present at three upcoming investor conferences in November 2024.
Benzinga · Jul 12, 2024
The Russell 2000 index of small caps surged over 6% this week, its best performance since October 2023, reaching 31-month highs. However, an analyst warns that the outlook is 'clouded by the Fed's concerns over the labor market', suggesting that rate cuts may not necessarily shield the economically sensitive index from a broader economic slowdown.
GlobeNewswire Inc. · May 29, 2024
MOUNTAIN VIEW, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 5, 2024, at 2:30 p.m. EDT in New York.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IGMS.
No results
No recent SID articles mention IGMS.
